| P50 | author | Gerhard Rogler | Q64750687 |
| P2093 | author name string | Hans H Herfarth | |
| | Peter D R Higgins | |
| P2860 | cites work | Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 |
| | Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee | Q33523446 |
| | Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. | Q35595821 |
| | Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis | Q37424635 |
| | Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms | Q37987352 |
| | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management | Q38049776 |
| | Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease | Q38098574 |
| | Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. | Q38121115 |
| | Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. | Q38186069 |
| | Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab | Q44742543 |
| | Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis | Q46428846 |
| | Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 |
| | The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. | Q51251490 |
| | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 |
| | Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 |
| | The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial | Q83008423 |
| | Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis | Q84341621 |
| | Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis | Q87263251 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 336-338 | |
| P577 | publication date | 2014-10-05 | |
| P1433 | published in | Clinical Gastroenterology and Hepatology | Q5133759 |
| P1476 | title | Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? | |
| P478 | volume | 13 | |